Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068033 | 1.00 | PIK3CD (0.50) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 | |
| SCHEMBL28575779 | 1.00 | PIK3CD (0.50) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 | |
| SCHEMBL28565071 | 0.79 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 | |
| SCHEMBL20061345 | 0.79 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 | |
| SCHEMBL20067857 | 0.75 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL20061344 | 0.75 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 | |
| SCHEMBL28565125 | 0.74 | PIK3CD (0.38) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL20061342 | 0.74 | PIK3CD (0.38) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL20068036 | 0.74 | PIK3CD (0.38) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL15226592 | 0.74 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107690433-B | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating PI3 kinase-associated diseases comprising the same as active ingredient | 韩国化学研究院 | 2021-04-09 | — | — | CN | disclosed |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | WEE2, WEE1, ITK | PIK3CD 14/4885PIK3CG 19/4885PIK3CB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.